Search

everythinglearnresearchcommunity

for

Search:↓

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Chemotherapy for breast cancer often causes significant and lasting hair loss.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Mesotherapy with dutasteride effectively treats hair loss with manageable side effects.

In post-menopausal women, signs of increased male hormones should be checked for possible ovarian cancer.

The treatment improved hair growth and was well-received without side effects.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Improving treatment plans can reduce hair loss and improve life quality for ovarian cancer patients.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Male hormones, or androgens, affect women's health in areas like mood and bone density, and hormone replacement therapy using antiandrogenic progestogens can improve mood disorders and alertness in menopausal women.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.

ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.

5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.

Testosterone in older women can increase bone density, muscle mass, fat mass, improve memory, and boost libido, but may cause nipple color changes.

Inhibiting certain enzymes made female rats more sensitive to low-level pain.

A rare ovarian tumor caused high testosterone in a postmenopausal woman, resolved by surgery.

Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.

Dutasteride works better than finasteride for hair loss, with both being safe to use.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

Upadacitinib improved multiple immune-related conditions in one patient.